Dr. Emily Drabant Conley is Chief Executive Officer of Federation Bio, a biotechnology company pioneering engineered bacterial cell therapies. The company’s first-in-class platform combines the power of genetic engineering and synthetic consortium design to control systemic immune responses and broad metabolic functions.

Previously, Dr. Conley spent over a decade at 23andMe, where she helped scale the company from 30 employees into the world’s leading platform for genetic-driven drug discovery. As Vice President of Business Development at 23andMe, she architected visionary partnerships across pharma and biotech. ​Dr. Conley currently serves on the boards of Federation Bio, TMRW, and Medrio, and formerly served on the boards of Lesbians Who Tech and the UCSF Alliance Health Project.

Dr. Conley has received numerous awards and honors, including Endpoints News’ 20 Biopharma Leaders Under 40, Business Insider’s 30 Leaders Under 40, and Google Ventures’ 25 Women Shaping the Future of Technology.

Prior to industry, Dr. Conley was a research fellow at the National Institutes of Health and is co-author on more than 35 academic publications. She received her Ph.D. in Neuroscience from Stanford University School of Medicine, where she held fellowships from the National Science Foundation and Department of Defense. She graduated summa cum laude from Vanderbilt University with a B.A.